| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SH3BGRL3 |
| Uniprot No | Q9H299 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-93aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMSGLRVYSTSVTGSREIKSQQSEVTRI LDGKRIQYQLVDISQDNALRDEMRALAGNPKATPPQIVNGDQYCGDYELF VEAVEQNTLQEFLKLA |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SH3BGRL3重组蛋白的3篇文献摘要概括(虚构示例，仅作格式参考)：
1. **文献名称**: *SH3BGRL3 promotes breast cancer metastasis via EGFR signaling activation*
**作者**: Li X, et al.
**摘要**: 研究发现SH3BGRL3重组蛋白在乳腺癌细胞中过表达，通过激活EGFR信号通路增强细胞迁移和侵袭能力，提示其作为潜在治疗靶点。
2. **文献名称**: *SH3BGRL3 interacts with Wnt/β-catenin pathway in colorectal cancer progression*
**作者**: Wang Y, et al.
**摘要**: 利用重组SH3BGRL3蛋白实验证实其与β-catenin结合，促进Wnt通路活性，导致结直肠癌细胞增殖和化疗耐药性增加。
3. **文献名称**: *SH3BGRL3 as a novel biomarker for acute myocardial infarction*
**作者**: Zhang H, et al.
**摘要**: 通过血清蛋白质组学分析发现SH3BGRL3重组蛋白在心肌梗死患者中显著上调，可能通过调节心肌细胞凋亡参与病理过程。
(注：以上文献为示例，实际研究中请通过PubMed或学术数据库检索真实文献。)
SH3BGRL3 (SH3 domain-binding glutamic acid-rich protein-like 3) is a member of the SH3BGR family, characterized by conserved SH3-binding domains and glutamic acid-rich regions. This small, evolutionarily conserved protein (approximately 17-20 kDa) contains an N-terminal SH3-binding motif and a C-terminal acidic amino acid cluster. Though its precise biological functions remain incompletely understood, SH3BGRL3 has been implicated in diverse cellular processes, including signal transduction, protein-protein interactions, and tumorigenesis.
Studies suggest SH3BGRL3 interacts with SH3 domain-containing proteins, potentially modulating pathways such as TGF-β and Wnt signaling. Its expression varies across tissues, with notable roles in cardiovascular development and cancer progression. In tumor contexts, SH3BGRL3 exhibits dual functionality: it acts as a tumor suppressor in hepatocellular carcinoma by inhibiting cell proliferation and migration, while paradoxically promoting metastasis in colorectal cancer through EMT activation. This context-dependent behavior highlights its complex regulatory mechanisms.
Recombinant SH3BGRL3 protein is typically produced using bacterial (E. coli) or mammalian expression systems, often fused with tags (e.g., His-tag, GST) for purification and detection. Its recombinant form enables functional studies, including binding partner identification, structural analysis, and pathway interrogation. Recent research explores its diagnostic potential as a cancer biomarker and therapeutic target, particularly in cancers showing aberrant SH3BGRL3 expression. However, further investigation is required to fully elucidate its molecular interactions and tissue-specific roles across physiological and pathological conditions.
×
